The Growing Role of CGM Data in Insurance and Employment Decisions

Continuous Glucose Monitors (CGMs) have transformed diabetes management from a reactive, finger-stick-based routine into a proactive, data-driven process. These devices generate a rich stream of real-time glucose readings, trend patterns, and time-in-range statistics that offer unprecedented insight into an individual’s metabolic health. As the value of this data becomes more widely recognized, insurers and employers are increasingly interested in accessing CGM data to inform underwriting, wellness program design, and even employment-related decisions. Yet with this interest comes a critical responsibility: ensuring that data sharing is conducted with full transparency, informed consent, and robust privacy protections. When the flow of sensitive health information is not handled openly, trust erodes, legal liabilities mount, and patients may hesitate to use life-saving technology. This article explores why transparent communication must be the foundation of any CGM data-sharing arrangement and outlines practical strategies for all parties involved.

What Transparency Means in the Context of CGM Data

Transparency in health data sharing goes far beyond a quick checkbox on a consent form. It means that patients are given clear, understandable information about exactly what data will be collected, who will have access to it, how it will be stored and protected, and for what specific purposes it will be used. When sharing CGM data with insurers or employers, this clarity becomes even more important because the stakes are high — data could influence insurance premiums, coverage eligibility, workplace accommodations, or even hiring decisions. Transparent communication also requires that patients are informed of any changes to data use policies and that they retain meaningful control over their data, including the ability to revoke consent at any time.

Why Transparent Communication Is Non-Negotiable

Building and Sustaining Trust

Trust is the currency of the patient–provider–payer relationship. When a patient shares CGM data with an insurer or employer, they are revealing deeply personal information about their health, daily habits, and even moments of vulnerability. If that information is later used in a way the patient did not expect or did not agree to, trust is shattered. Transparent communication reassures patients that their data will be handled with respect and that their interests are prioritized. Organizations that invest in clear, proactive communication — including explaining the benefits of data sharing for population health or personalized care — are far more likely to earn and retain patient confidence.

In the United States, health data is protected under the Health Insurance Portability and Accountability Act (HIPAA), which sets strict standards for the use and disclosure of protected health information. Employers and insurers that fall under HIPAA’s purview must obtain valid authorization before using CGM data for purposes beyond treatment, payment, or health care operations. Transparency is not just an ethical ideal; it is a legal requirement. Failure to communicate clearly about data use can lead to significant fines, reputational damage, and lawsuits. Moreover, many states have enacted additional privacy laws (e.g., California’s Consumer Privacy Act) that impose further obligations. Transparent communication helps organizations stay compliant by ensuring that patients understand and consent to each specific use of their data.

Empowering Patients Through Knowledge

When patients understand how their CGM data will be used, they are better equipped to make informed decisions about their own care and about whether to participate in employer wellness programs or insurer-sponsored disease management initiatives. Clear communication demystifies the data-sharing process and allows patients to evaluate the risks and benefits. For example, a patient who knows that their insurer will only receive aggregated, de-identified data for quality improvement purposes may feel more comfortable sharing than if the data were used to adjust individual premiums. Transparency turns patients from passive data subjects into active, informed participants.

The Stakeholder Perspective: Insurers, Employers, and Patients

Insurers: Balancing Risk Assessment with Privacy

Health insurers have a legitimate interest in CGM data for actuarial risk assessment, care management, and evaluating the effectiveness of diabetes treatment programs. However, the line between using data to improve care and using it to penalize patients can be thin. Transparent insurers explicitly state whether data will be used for underwriting, premium adjustments, or claims decisions. They also explain how they protect data from being used for discriminatory purposes. HIPAA regulations provide a framework, but individual insurers must go further by adopting plain-language policies, offering opt-out options, and providing real-world examples of how data improves health outcomes without harming individuals.

Employers: Supporting Wellness Without Overstepping

Employers are increasingly offering wellness programs that include CGM devices as a benefit for employees with diabetes. The promise is attractive: better glucose control leads to fewer sick days, lower health care costs, and a more productive workforce. Yet employees fear that their CGM data might be used to justify termination, deny promotions, or raise health insurance premiums. Transparent employers make it clear that participation is voluntary, that individual data will never be shared with managers or HR unless the employee explicitly allows it, and that data will only be used in aggregate form to shape program benefits. Some leading companies publish a Data Use Charter that outlines these protections in accessible language. EEOC guidelines also restrict how employers can use genetic and health information, adding another layer of legal protection that should be communicated clearly.

Patients: Navigating Rights and Risks

For patients, the decision to share CGM data can feel like a trade-off between better care and loss of privacy. Transparent communication gives them the tools to navigate this decision. Patients should be told that they have the right to:

  • Know exactly which data points (e.g., time-in-range, average glucose, hypoglycemic events) are being collected.
  • Specify the duration for which data may be used.
  • Withdraw consent at any time without penalty.
  • Request deletion of their data after the agreed-upon period.
  • Receive a clear, written explanation of how data will be stored and secured.
Patient advocacy organizations, such as the American Diabetes Association, offer resources to help individuals understand their rights and ask the right questions before agreeing to share CGM data.

Privacy and Security: The Cornerstones of Transparent Sharing

Data Encryption and Access Controls

Transparent communication is hollow if the underlying data security measures are weak. Organizations that collect CGM data must implement industry-standard encryption both in transit and at rest. Access logs should be maintained to track who views or exports data. Patients should be informed of these technical safeguards in plain language — not buried in a privacy policy. For example, a simple statement like “Your data is encrypted and only three clinical care coordinators have access to it” provides far more transparency than a paragraph of legal jargon.

De-identification and Aggregation

Whenever possible, insurers and employers should use de-identified or aggregated CGM data for analysis. De-identification removes direct identifiers (name, Social Security number, etc.) and can also strip out indirect identifiers like zip codes or dates of birth. Aggregation combines data from many individuals so that no single person’s pattern is visible. Transparent organizations clearly state whether they will use individual-level data or only aggregate statistics, and they explain why. For instance, an insurer might use aggregate data to determine that its diabetic members who use CGMs have 20% fewer hospitalizations — a valuable insight that does not require exposing any one member’s data.

Consent should not be a one-time event. Transparent communication means obtaining initial consent and then providing periodic reminders about how data is being used. If an insurer decides to repurpose CGM data for a new research study, it must obtain fresh consent. If an employer changes its wellness program vendor, employees must be informed. Some organizations use a dynamic consent model, where patients can log into a portal at any time to view their current data-sharing permissions and adjust them. This approach transforms consent from a static signature into an active, ongoing dialogue.

Best Practices for Implementing Transparent Communication

Develop Clear, Accessible Policies

Every organization that handles CGM data should have a written data-sharing policy written at a sixth- to eighth-grade reading level. Avoid legalese. Use bullet points, short sentences, and concrete examples. The policy should cover:

  • What data is collected (e.g., sensor glucose readings every 5 minutes, times of meals, exercise markers).
  • How long the data will be kept.
  • Who has access (individual clinicians, data analysts, wellness coaches, third-party vendors).
  • The purpose (quality improvement, care coordination, eligibility decisions — specify which).
  • The right to opt out and consequences (if any — ideally none besides loss of program benefits).
Post the policy prominently on websites and in enrollment materials.

Offer Layered Notices and Multiple Touchpoints

Not all patients learn the same way. Some prefer reading a brochure; others want a short video explanation; many appreciate a one-on-one conversation with a nurse or data privacy officer. Provide information in multiple formats and at multiple stages — during enrollment, annually, and whenever policies change. Use a layered notice: a short summary with key points, followed by a more detailed document for those who want it.

Train Staff and Partners

Everyone who interacts with patients — from insurance customer service representatives to employer wellness coordinators — must understand the transparency policies and be able to answer questions confidently. They should never downplay privacy risks or pressure patients into sharing more data than needed. Regular training ensures that the spirit of transparency is carried through every touchpoint.

Create an Opt-Out Mechanism That Is Easy and No-Fault

Patients should be able to opt out of CGM data sharing at any time, and the process should be straightforward — a phone call, an email, or a click on a portal. Importantly, opting out should not result in reduced quality of care or retaliation. An employer, for instance, should still provide standard diabetes coverage even if an employee declines to share CGM data. Transparent communication includes being honest about what happens when someone opts out: the patient keeps using the CGM, but the data is not used for program analytics.

Challenges and How to Overcome Them

Low Health Data Literacy

Many patients do not fully understand what CGM data reveals or how it might be used against them. An insurer might use the data to exclude coverage for certain complications, or an employer might infer that an employee cannot handle stress based on glucose variability patterns. To address this, organizations must invest in patient education that goes beyond basic consent forms. Use analogies, infographics, and real-life scenarios. For example: “Your CGM data shows your blood sugar patterns. We will use it to suggest when you should schedule meetings to avoid lows. We will not share it with your supervisor.”

Risk of Discrimination

Even with the best intentions, CGM data can be misused. There is a real concern that insurers could charge higher premiums or deny coverage based on poor glucose control, or that employers could discriminate against applicants with diabetes. Transparent communication must include a clear statement of non-discrimination policies. Organizations should also be aware of the FTC’s guidance on health data and state laws that prohibit discriminatory use of health information. Proactive disclosure of safeguards — such as requiring a human review before any adverse action — builds trust.

Keeping Up with Technology

CGM technology evolves rapidly, with new sensors, longer wear times, and integrations with smartphone apps. Transparency policies must be updated as capabilities change. For example, a CGM that also tracks heart rate or sleep adds new dimensions of sensitive data. Organizations should commit to reviewing their policies every six months and notifying patients of any changes that affect data collection or use.

Looking Ahead: The Future of Transparent CGM Data Sharing

As artificial intelligence and machine learning become more common in analyzing CGM data, transparency will become even more critical. Algorithms that predict hypoglycemia or stratify risk may inadvertently amplify biases or invade privacy in unforeseen ways. Patients must understand that their data is feeding these systems and have a say in whether they want to be included. Some experts advocate for a “algorithmic transparency” label that explains how a model uses its data and what decisions it influences.

Regulatory bodies are also paying closer attention. The FDA and FTC have both issued statements about the importance of transparency in digital health data. We may soon see new federal or state laws that mandate specific consent and communication practices for CGM and other wearable sensor data. Early adopters of transparent communication will be better positioned to comply and to lead the industry standard.

Conclusion: Transparency as a Continuous Commitment

Sharing CGM data with insurers and employers holds tremendous potential for improving diabetes care, reducing costs, and personalizing wellness programs. But that potential can only be realized if patients trust the system. Trust is built on transparency — not a one-time consent form but an ongoing, honest dialogue about what data is collected, why, how it is protected, and what control the patient retains. By prioritizing clear communication, robust privacy protections, and patient empowerment, healthcare organizations, insurers, and employers can create a data-sharing ecosystem that respects individuals while delivering the benefits of aggregated health intelligence. The path forward requires vigilance, empathy, and a willingness to put the patient’s right to understand and choose at the center of every data exchange.